CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Abstract

Combined post-hoc analysis of afatinib efficacy in uncommon EGFR mutations.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(15)00026-1

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 30 references

Cited by

See all 1,002

Metadata

Authors
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., Massey, D., Zazulina, V., & Wu, Y.-L.
Affiliations
  • National Taiwan University (TW)
  • Massachusetts General Hospital (US)
  • Prince of Songkla University (TH)
  • Taipei Veterans General Hospital (TW)
  • Chinese University of Hong Kong (HK)
  • Wakayama Medical University (JP)
  • University of California, Irvine (US)
  • Shanghai Pulmonary Hospital (CN)
  • Boehringer Ingelheim (United Kingdom) (GB)
  • Guangdong General Hospital (CN)
Corresponding author
Wu, Yi-Long
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-07
Volume
16
Issue
7
Pages
830-838
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2139804581
Cited by
1,002
References
30
Citations by year
2026: 49 · 2025: 79 · 2024: 92 · 2023: 102 · 2022: 117 · 2021: 119 · 2020: 117 · 2019: 96 · 2018: 88 · 2017: 61 · 2016: 57 · 2015: 22
FWCI
60.02
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
afatinib, non-small cell lung cancer, EGFR mutation, uncommon EGFR mutations, exon 20 insertion, EGFR tyrosine kinase inhibitors, lung adenocarcinoma, Asian patients, ethnicity
MeSH terms
Afatinib, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Invasiveness, Neoplasm Staging, Quinazolines, Gene Expression Regulation, Neoplastic, Confidence Intervals, Survival Analysis, Treatment Outcome, Disease-Free Survival, Genes, erbB-1, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. https://app.cochat.ai/papers/10.1016/s1470-2045(15)00026-1
The paper
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., Massey, D., Zazulina, V., & Wu, Y.-L. (2015). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00026-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.